Anna Sitthi-Amorn

649 total citations
12 papers, 74 citations indexed

About

Anna Sitthi-Amorn is a scholar working on Pediatrics, Perinatology and Child Health, Hematology and Oncology. According to data from OpenAlex, Anna Sitthi-Amorn has authored 12 papers receiving a total of 74 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pediatrics, Perinatology and Child Health, 5 papers in Hematology and 4 papers in Oncology. Recurrent topics in Anna Sitthi-Amorn's work include Childhood Cancer Survivors' Quality of Life (5 papers), Acute Lymphoblastic Leukemia research (4 papers) and Neutropenia and Cancer Infections (3 papers). Anna Sitthi-Amorn is often cited by papers focused on Childhood Cancer Survivors' Quality of Life (5 papers), Acute Lymphoblastic Leukemia research (4 papers) and Neutropenia and Cancer Infections (3 papers). Anna Sitthi-Amorn collaborates with scholars based in United States, Türkiye and Australia. Anna Sitthi-Amorn's co-authors include James M. Hoffman, Jonathan D. Burlison, Lindsay Blazin, Chindo Hicks, Gail Megason, Cynthia Karlson, Aditya Sharma, Shankar Giri, Memory Tekere and Liza‐Marie Johnson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Pediatric Blood & Cancer.

In The Last Decade

Anna Sitthi-Amorn

9 papers receiving 71 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Sitthi-Amorn United States 5 26 19 17 14 14 12 74
Laura Labonté Canada 5 9 0.3× 20 1.1× 5 0.3× 15 1.1× 21 1.5× 12 181
Winston Cheung Australia 6 39 1.5× 12 0.6× 34 2.0× 15 1.1× 3 0.2× 7 78
Sarah J. Parker United States 5 16 0.6× 4 0.2× 9 0.5× 12 0.9× 3 0.2× 18 74
Hani Al‐Najjar Jordan 6 9 0.3× 17 0.9× 5 0.3× 4 0.3× 6 0.4× 19 70
Kevin Lai Australia 4 8 0.3× 3 0.2× 4 0.2× 15 1.1× 15 1.1× 9 68
K. Schäfer-Eckart Germany 5 3 0.1× 26 1.4× 21 1.2× 13 0.9× 18 1.3× 7 125
Vanessa Msosa Malawi 5 8 0.3× 48 2.5× 11 0.6× 2 0.1× 14 1.0× 12 89
Grant Vallance United Kingdom 6 6 0.2× 44 2.3× 3 0.2× 40 2.9× 35 2.5× 14 115
Panchali Sarmah United Kingdom 4 11 0.4× 45 2.4× 7 0.4× 12 0.9× 10 0.7× 6 89
Amjad Siraj Memon Pakistan 7 8 0.3× 64 3.4× 5 0.3× 11 0.8× 21 1.5× 19 125

Countries citing papers authored by Anna Sitthi-Amorn

Since Specialization
Citations

This map shows the geographic impact of Anna Sitthi-Amorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Sitthi-Amorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Sitthi-Amorn more than expected).

Fields of papers citing papers by Anna Sitthi-Amorn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Sitthi-Amorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Sitthi-Amorn. The network helps show where Anna Sitthi-Amorn may publish in the future.

Co-authorship network of co-authors of Anna Sitthi-Amorn

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Sitthi-Amorn. A scholar is included among the top collaborators of Anna Sitthi-Amorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Sitthi-Amorn. Anna Sitthi-Amorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Rodríguez‐Otero, Paula, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2024). Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.. Journal of Clinical Oncology. 42(16_suppl). 7502–7502. 9 indexed citations
3.
Sitthi-Amorn, Anna, Emily Denton, Saman K. Hashmi, et al.. (2022). Improving Blood Product Transfusion Premedication Plan Documentation: A Single-institution Quality Improvement Effort. Pediatric Quality and Safety. 7(3). e572–e572.
4.
Sitthi-Amorn, Anna, Anna Vinitsky, Jonathan D. Burlison, et al.. (2022). Quality improvement knowledge in pediatric hematology/oncology physicians: A need for improved education. Pediatric Blood & Cancer. 69(8). e29794–e29794. 1 indexed citations
5.
Sitthi-Amorn, Anna, Brian L. Abbott, Aditya Sharma, et al.. (2021). Reducing Time to Discharge after Chemotherapy by Standardizing Workflow and Providing Outpatient Intravenous Hydration. Pediatric Quality and Safety. 6(4). e415–e415.
6.
Sharma, Aditya, Anna Sitthi-Amorn, Joshua Wolf, et al.. (2020). Outcomes and Disposition of Oncology Patients With Non-neutropenic Fever and Positive Blood Cultures. Journal of Pediatric Hematology/Oncology. 43(2). 47–51. 6 indexed citations
7.
Blazin, Lindsay, Anna Sitthi-Amorn, James M. Hoffman, & Jonathan D. Burlison. (2020). Improving Patient Handoffs and Transitions through Adaptation and Implementation of I-PASS Across Multiple Handoff Settings. Pediatric Quality and Safety. 5(4). e323–e323. 33 indexed citations
8.
Sitthi-Amorn, Anna & Anderson B. Collier. (2016). Off-therapy procedures are not beneficial in pediatric B-cell acute lymphoblastic leukemia. Pediatric Hematology and Oncology. 33(3). 151–156. 2 indexed citations
9.
Hicks, Chindo, Anna Sitthi-Amorn, Jessica Douglas, et al.. (2016). Molecular Analysis of Central Nervous System Disease Spectrum in Childhood Acute Lymphoblastic Leukemia. Clinical Medicine Insights Oncology. 10. 5–15. 10 indexed citations
10.
Sitthi-Amorn, Anna, et al.. (2015). Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia. Clinical Medicine Insights Oncology. 9. 51–60. 4 indexed citations
11.
Hicks, Chindo, et al.. (2014). Integrative Genomic Analysis for the Discovery of Biomarkers in Prostate Cancer. Biomarker Insights. 9. BMI.S13729–BMI.S13729. 8 indexed citations
12.
Sitthi-Amorn, Anna, et al.. (2013). Molecular Basis Of Minimal Residual Disease In Subtypes Of Pediatric B Cell Acute Lymphoblastic Leukemia. Blood. 122(21). 1390–1390. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Labonté Breakdown of academic impact, for papers by Winston Cheung Breakdown of academic impact, for papers by Sarah J. Parker Breakdown of academic impact, for papers by Hani Al‐Najjar Breakdown of academic impact, for papers by Kevin Lai Breakdown of academic impact, for papers by K. Schäfer-Eckart Breakdown of academic impact, for papers by Vanessa Msosa Breakdown of academic impact, for papers by Grant Vallance Breakdown of academic impact, for papers by Panchali Sarmah Breakdown of academic impact, for papers by Amjad Siraj Memon
Rankless by CCL
2026